Trexon

Quick links to important sections

Trexon

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Trexon

Trexon is a prescription-only medicine centered on the active ingredient Naltrexone (INN), which the U.S. Food and Drug Administration (FDA) formally classifies as an Opioid Antagonist. This synthetic compound is fundamentally used to support patients managing substance use disorders. Pharmacological studies have consistently shown that Naltrexone is a reliable agent for maintaining abstinence in appropriate patient populations.


Quick Facts

Property Description
Active ingredient Naltrexone (INN)
Form Oral tablet and Intramuscular injection
Pharmacological class Opioid Antagonist
Common use Supporting abstinence
Origin Synthetic

What Type of Medicine is Trexon?

Trexon's definitive pharmacological identity is a pure opioid antagonist, meaning the Naltrexone molecule acts by competitively binding to opioid receptors in the central nervous system. This specific physiological action ensures it does not possess any opioid agonist properties, which are the characteristics associated with pain relief or sedation. The drug is therefore structurally and functionally different from general painkillers, making it a highly specific tool for recovery support.

Composition and Available Forms

The medication is supplied as a Single active ingredient product, consisting solely of Naltrexone combined with necessary excipients. Trexon is available in two distinct preparations for varying route of administration: the daily oral tablet and a specialized, long-acting extended-release intramuscular injection. The injectable form is designed to deliver the synthetic compound over an extended timeframe, which assists in simplifying the dosing schedule.

The General Benefit: A Receptor Blocker

The core general purpose of this agent is to help reduce the persistent psychological desire, or craving, for substances by maintaining a receptor blockade. This mechanism of effect eliminates the possibility of feeling intoxication or euphoria, which is the primary benefit for patients in recovery from opioid use disorder or alcohol use disorder. By blocking the reward signal, Trexon supports patients in their goal of sustained abstinence.

What side effects are possible with Trexon?

Possible Side Effects and Safety Information

The medicine's safety profile is formally organized by regulatory authorities, classifying potential adverse reactions by both frequency and the physiological system affected.

Official Adverse Reaction Groupings

Category Examples from Regulatory Sources
Very Common Reactions Headache, nausea, vomiting, dizziness, somnolence, constipation.
Common Reactions Insomnia, anxiety, abdominal pain, joint pain (arthralgia), muscle pain (myalgia), decreased appetite, and fever.
System-Organ Classes Gastrointestinal Disorders, Nervous System Disorders, Psychiatric Disorders, Musculoskeletal and Connective Tissue Disorders, and Hepatobiliary Disorders.

Serious Safety Considerations

The official labeling documents highlight several serious adverse reactions, including the risk of hepatotoxicity (liver injury) and reports of depression and suicidal ideation/attempts observed in clinical settings. There is also a specific safety concern regarding the body's increased sensitivity to opioids after discontinuing the treatment, which increases the risk of overdose if opioids are later used. For the injectable formulation, severe injection site reactions (e.g., necrosis, abscess) and eosinophilic pneumonia are documented as serious events.


Population and Time-Related Safety Patterns

Regulatory safety constraints require an opioid-free interval of a minimum of seven to ten days before starting the medication to prevent the precipitation of acute withdrawal syndrome. Regarding specific patient populations, caution is advised for individuals with renal impairment, and the medicine is contraindicated in those with acute hepatitis or liver failure. Liver function monitoring is recommended prior to and during therapy.

Overdose and Emergency Response

The primary life-threatening concern documented in regulatory labeling is the vulnerability to a potentially fatal opioid overdose. This severe risk arises from the reduced opioid tolerance established during treatment, making patients acutely sensitive to opioids, particularly if used after treatment discontinuation, at the end of a dosing interval, or in an attempt to overcome the blockade. Such an event can result in life-threatening opioid intoxication, potentially leading to respiratory compromise or arrest and circulatory collapse.

Regulators mandate that patients seek immediate medical attention and call emergency services immediately for any suspected opioid overdose. For the emergency management of this risk, official labeling strongly considers the prescribing of naloxone.

Separately, taking excessive doses of the medicine itself may lead to hepatocellular injury. Patients must seek medical attention if symptoms of acute hepatitis appear, such as fever, persistent vomiting, abdominal pain, or jaundice. Treatment for an overdose of the medicine, for which no specific antidote is known, is generally described as symptomatic and supportive.

Therapeutic Uses of Trexon

What Trexon Treats: Main Uses and Benefits

Trexon is a medicine applied in comprehensive management programs. It is commonly used across conditions presenting with acute episodes, such as those related to alcohol use disorder (AUD) and opioid use disorder (OUD). It supports individuals by helping to ease the overall symptom burden linked to these conditions.


The medication is generally used in clinical settings that involve acute or unstable symptom patterns, for example, after an individual has completed detoxification. It may assist with maintaining functional stability and contributes to easing discomfort during periods of heightened symptoms. The medicine is considered relevant for easing symptoms that create noticeable physiological strain and those related to heightened physiological activity. It helps improve day-to-day comfort during symptomatic periods and may assist with providing supportive relief when symptoms interfere with routine activities.

Quick Fact: Relief for Symptoms that Interfere with Daily Functioning

Regulatory References

  1. NIH MedlinePlus overview on Naltrexone

Eligibility and Restrictions for Use

Trexon is an opioid antagonist strictly approved for use in adult patients (age 18 and older) for alcohol use disorder and opioid use disorder.

Contraindications: Who Must Not Use Trexon

Official regulatory documents state that Trexon is absolutely contraindicated in patients with:

  • Current Opioid Status: Individuals receiving opioid analgesics, those with physiologic opioid dependence, those in acute opioid withdrawal, or those with a positive urine screen for opioids.
  • Liver Health: Patients with acute hepatitis or liver failure.
  • Allergy: Individuals with a known hypersensitivity to naltrexone or any component of the formulation.

Conditional and Restricted Use

Use is subject to restrictions or caution for certain populations:

  • Pediatric Use: Not recommended for children and adolescents under 18 years, as safety and efficacy have not been established.
  • Organ Impairment: Caution is advised for patients with moderate to severe renal (kidney) impairment and those with existing impaired hepatic (liver) function.
  • Pregnancy/Lactation: Use during pregnancy is generally categorized as a restriction (FDA Category C). Breastfeeding is not recommended.

What should I know about interactions with other medicines?

The interaction profile for Trexon (Naltrexone) is strictly defined by its activity as an opioid antagonist, which necessitates specific, mandated restrictions.

Interaction-Related Restrictions

Co-administration of Trexon is contraindicated with all Opioid Analgesics and any Opioid-Containing Medicines, including certain preparations for cough or diarrhea, as this can antagonize the opioid effects and trigger a severe acute withdrawal syndrome. Treatment must not be initiated in patients with physiologic opioid dependence or those in acute opioid withdrawal. A mandatory opioid-free interval of 7 to 10 days is required prior to starting Trexon.

Documented Pharmacodynamic and Exposure Interactions

Regulatory documents also outline several pharmacokinetic and pharmacodynamic interactions. Co-administration with the antipsychotic Thioridazine has been reported to cause lethargy and somnolence. Caution is advised when using other CNS Depressants due to potential additive sedative effects. In terms of drug exposure, Naltrexone co-administration increases the plasma concentration of Acamprosate. Conversely, drugs like Bremelanotide may lead to decreased naltrexone systemic exposure. For a specific fixed-dose combination product, consumption with a high-fat meal results in a significant increase in Naltrexone systemic exposure. Individuals with hepatic impairment (liver cirrhosis) may show higher drug concentrations, and caution is officially advised in those with renal impairment due to the drug's excretion pathway.

Mechanism of Action

Trexon exerts its primary action as a dual reuptake inhibitor of Norepinephrine (NET) and Serotonin (SERT) transporters, showing a higher affinity for NET. This mechanism prevents the reabsorption of these neurotransmitters into the presynaptic terminal, leading to a sustained increase in their concentration within the synaptic cleft and enhancing monoaminergic signal transmission.

This elevated norepinephrine availability enhances the descending inhibitory pathways that project from the brainstem to the dorsal horn of the spinal cord. Functionally, this enhances the central dampening of nociceptive signal transmission at the spinal level. Additionally, Trexon acts as an antagonist at specific alpha1-adrenergic receptors, which modulates sympathetic outflow to the periphery. This secondary effect contributes to a reduction in peripheral vasoconstrictive drive, resulting in altered systemic vascular resistance.

Dosage and Administration Information

Administration Method

Trexon is typically administered through a specific route as determined by a healthcare provider. The method of delivery is designed to ensure the medication is processed effectively by the body. Depending on the formulation, it may require preparation or the use of specific medical equipment.

Routine and Consistency

Establishing a regular schedule is often a key component of management. Maintaining consistency in the timing of the medication helps to keep steady levels of the substance in the system. If a transition in the routine is necessary, it is usually managed under professional guidance.

Handling and Storage

Proper handling of the medication involves maintaining the integrity of the product until the point of use. This includes:

  • Storing the medication at the temperature specified on the packaging.
  • Keeping the product in its original container to protect it from light or moisture.
  • Ensuring the medication is kept out of reach of unauthorized individuals.

Observation and Monitoring

While using Trexon, individuals are typically monitored by healthcare professionals to evaluate how the body is responding. This may involve periodic check-ups or laboratory tests. It is important for individuals to remain aware of their physical response and maintain open communication with their care team during the process.

Recent Clinical Evidence

Trexon: Recent Clinical Evidence


Evidence for Use in Alcohol Use Disorder (AUD)

The available research for Trexon in the context of Alcohol Use Disorder (AUD) primarily consists of randomized controlled trials (RCTs). These studies were used in research exploring how measurements in drinking behavior were recorded over defined, usually short-term, time intervals. Researchers explored how the daily oral tablet or the extended-release injection compared to an inactive substance. The outcomes studied in these trials included measurements of the frequency of heavy drinking days, the overall number of drinking days, and patient-reported scores used to evaluate craving intensity. Findings describe the measurement patterns recorded for heavy drinking days compared to the control groups, and evidence contributes to understanding symptom patterns, particularly concerning the intensity of craving, though these reports describe group patterns, not personal outcomes.

Evidence for Use in Opioid Use Disorder (OUD)

Studies focusing on Trexon for Opioid Use Disorder (OUD) were primarily designed to assess its use in the context of relapse management following detoxification. Research was concentrated on randomized controlled trials (RCTs), particularly evaluating the effects of the extended-release injectable formulation. In these studies, researchers examined outcomes linked to specific metrics, monitoring patients for confirmed instances of opioid use and the length of time patients remained engaged in the treatment program (retention). Trials reported data on the frequency of relapse events observed in patients assigned to the medication group compared to the control group during the study period.

Evidence Gaps and Limitations

Research for Trexon is largely derived from studies with limited follow-up durations. Long-term effects are not fully established regarding extended follow-up outcomes beyond the initial six months of most structured trials. Data for certain groups, such as children, adolescents, or older adults (seniors), remains insufficient, and subgroup findings are uncertain. Additionally, the evidence base highlights that comparative evidence is lacking between certain treatment environments or different forms of the medication over sustained periods. Research describes what has been observed so far, but it does not determine whether initial findings are fully maintained over many years.

Frequently Asked Questions (FAQ)

Common questions about Trexon (FAQ)

Q: How long does Trexon stay in your system after you stop taking it?

Official regulatory documents do not specify the exact time it takes for the body to fully eliminate Trexon (pharmacokinetics). However, the product labeling emphasizes a specific safety concern: after stopping the medication, the body has an increased sensitivity to opioids, which can increase the risk of accidental overdose if opioids are later used.

Q: Can Trexon be taken with common over-the-counter pain relievers?

Regulatory product information strictly contraindicates (forbids) the use of Trexon with all Opioid Analgesics and any other Opioid-Containing Medicines. This includes certain preparations used for cough or diarrhea. For non-opioid over-the-counter pain relievers, the official documents do not list them as specific contraindications.

Q: Is Trexon considered a 'strong' or 'weak' medication?

The official labeling describes Trexon as a reliable agent to support patients in maintaining abstinence. From a pharmacological perspective, Trexon is classified as a pure opioid antagonist. This means the compound works by occupying opioid receptors.

Q: How is Trexon different from Drug-X, which is used for similar conditions?

Trexon’s definitive pharmacological classification, as stated by regulatory authorities, is a pure opioid antagonist. Its defining characteristic is its role as an opioid antagonist, meaning it occupies opioid receptors. Official information focuses on describing this specific pharmacological classification and function.

Q: Is Trexon safe to use for older adults (seniors)?

Official prescribing documents and research evidence indicate that data for older adults (seniors) remains insufficient to fully establish the drug's effects and safety profile in this age group. The lack of established data means use is typically restricted or caution is required for this population.

Q: Are there any specific foods or drinks (like caffeine or alcohol) to avoid while on Trexon?

Official product information notes a specific drug exposure interaction regarding food. For a specific fixed-dose combination product, co-administration with a high-fat meal has been reported to cause a significant increase in the medication's systemic exposure. General restrictions for other specific foods or drinks are not defined.

Q: What happens if you suddenly stop using Trexon?

Official regulatory warnings emphasize a serious safety risk following the discontinuation of Trexon. The loss of the drug's blocking action results in the body having increased sensitivity to opioids, which increases the risk of accidental overdose if opioids are later used. Regulatory warnings focus on this specific risk. Trexon itself does not possess the properties of an opioid.

Q: Does Trexon interact with common cold or allergy medications?

Regulatory documentation strictly contraindicates the use of Trexon with Opioid-Containing Medicines, which can include some common cough and diarrhea preparations. Additionally, caution is advised when using other medications that act as CNS Depressants (medicines that slow down brain activity) due to the potential for increased sedative effects.

Q: Is Trexon a medication that requires long-term use?

According to the official prescribing information, there is no fixed duration of use defined for Trexon treatment. However, the regulatory guidance notes that an initial treatment course of three months is typically considered in the context of use.

Q: Can I drive or operate machinery while taking Trexon?

The product labeling lists both dizziness and somnolence (sleepiness) as Very Common Reactions experienced by patients. These effects may lead to impairment, meaning the ability to drive or safely operate heavy machinery could be affected.

Q: What happens in the body when Trexon is metabolized?

Regulatory documents do not provide a detailed breakdown of the exact metabolic process. They do, however, describe that drug exposure can be altered by co-administering certain other medicines. Official caution is required for use in patients with hepatic (liver) or renal (kidney) impairment, which indicates the importance of these organs in the drug's processing and excretion pathway.

Q: Does Trexon contain any ingredients that might cause an allergic reaction?

Official regulatory documentation states that Trexon is contraindicated (should not be used) in individuals who have a known hypersensitivity or allergy. This restriction applies to both the active ingredient, Naltrexone, and any other component of the formulation (non-active ingredients or excipients).

Q: What is the typical timeframe for a doctor to review Trexon's effectiveness?

Official prescribing documents state that an initial treatment course of three months is typically considered. This duration may indicate a common timeframe for healthcare providers to review the medication's ongoing effects.

Q: Can Trexon be taken with other prescription medications for chronic conditions?

Regulatory labeling advises caution or lists specific contraindications when Trexon is used alongside certain classes of medication. This includes all opioid-containing medicines, the antipsychotic Thioridazine, and general CNS Depressants.

Q: What should I do if I forget to take Trexon for one day?

Official documents for the oral form mention that a flexible dosing regimen may be utilized to support adherence. For example, the prescribing information notes that a regimen may include taking 100 mg on Monday and Wednesday, and 150 mg on Friday. This information serves to clarify potential schedule flexibility.

Q: Is Trexon a controlled substance?

Regulatory classification defines Trexon as an Opioid Antagonist. This means the compound blocks the effects of opioids by binding to the receptors. The drug does not possess the opioid agonist properties associated with pain relief or dependency.

Q: What is the difference between Trexon and its generic version?

The medication is centered on the single active ingredient Naltrexone (INN), which is the generic compound. The official product information covers the effects and safety of this active compound. Trexon is supplied in two distinct preparations: an oral tablet and an extended-release injection.

How should Trexon be stored and disposed of?

Storage and Disposal Requirements

Official regulatory guidelines define specific storage requirements for both forms of Naltrexone (Trexon).

Product Form Mandatory Storage Condition
Oral Tablets Store at 20 C to 25 C (68 F to 77 F) (Controlled Room Temperature).
Extended-Release Injection Store in a refrigerator at 2 C to 8 C (36 F to 46 F). Do not freeze.

The tablets must be dispensed in a tight container. If the injection is removed from refrigeration, it can be maintained for no more than seven days at temperatures up to 25 C. All forms must be stored out of the sight and reach of children.

For disposal, utilize a medicine take-back program for unused product. Used needles and syringes from the injectable form must be immediately placed in an FDA-cleared sharps disposal container.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Trexon found in:

A-Z Index: